

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES

P.O. BOX 119, HONOLULU, HAWAI'I 96810-0119 Ph: (808) 586-6000 | Fax: (808) 586-1922 ETS.HAWAII.GOV

April 18, 2022

The Honorable Ronald D. Kouchi,
President, and
Members of The Senate
Thirty-First State Legislature
Hawaii State Capitol, Room 409
Honolulu, Hawaii 96813

The Honorable Scott K. Saiki, Speaker, and Members of The House of Representatives Thirty-First State Legislature Hawaii State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawaii Department of Health Hawaii BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at http://ets.hawaii.gov (see "Reports").

Sincerely,

DOUGLAS MURDOCK Chief Information Officer

State of Hawai'i

Attachment (2)



Hawaii BHA Integrated Case Management System Project – *Phase 3*

Final IV&V Report for the period of

March 1 - March 31, 2022

Final submitted: April 14, 2022



Agenda

Executive Summary

IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends





Executive Summary

The Project deployed R3.22 to production on 3/17/2022. Quality issues continue to persist as there were five (5) reported post-production defects. A Mid-Sprint deployment was completed on 3/31/2022 to fix the critical and high defects. An initial Root Cause Analysis (RCA) was performed after the release and a formal RCA is planned for early April.

As previously reported, IV&V continues to remain concerned about BHA staff shortages as the schedules for 'big boulder' interfaces functionality as well as internal initiatives continued to slip in March. Also, a recent deployment team member transition has the potential to negatively impact the project's ability to deploy code if not addressed appropriately and in a timely manner. IV&V will continue to closely monitor these items moving forward.

Jan	Feb	Mar	Category	IV&V Observations		
R R Sprint Planning			BHA's new ITS4 started work on 3/1/2022 and is assigned to the automated regression testing effort. DDD is waiting on approval authority to post its open IT position. One key CAMHD resource is unavailable through early April, and another will be partially allocated to an MQD initiative in May. A current deployment team member has transitioned to another role and mitigation efforts are in progress to compensate for this transition. The criticality rating for this category remains Red (high) for the March reporting period.			
G	G User Story (US) Validation There are no active findings in User Story (US) Validation category which remains Green (low criticality) for the March reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.					
Y	V V V I I I I I I I		BHA continued its efforts to select an automated regression tool as additional demos are being scheduled for the month of April and it is anticipated a tool will be selected during April or May.			
R Deployment April will provide more details on the source of these issues. As mentioned above,		production defects are tied to the release/deployment. A formal RCA planned for early April will provide more details on the source of these issues. As mentioned above, IV&V is concerned about the transition of a current deployment team member to another role and				




Executive Summary

Jan	Feb	Mar	Category	IV&V Observations		
G	G	G	OJT and KT Sessions	The criticality rating for the OJT and KT Sessions category remains Green (low) for the March reporting period with no active findings.		
G	G	G	Targeted KT	A Calculator 3.0 Knowledge Transfer session was conducted on March 24 th between RSM and BHA to review inline coding comments. This category remains Green (low criticality) for the March reporting period and IV&V will continue to monitor.		
G	Project Performance Metrics The Project implemented 163 User Story Points for Release 3.22 exceeding the estimated 161 User Story Points. Overall, the project continues to exceed expectations volume of work performed. IV&V will keep the criticality rating for this category Green (low) and will continue to monitor this category moving forward.			estimated 161 User Story Points. Overall, the project continues to exceed expectations for volume of work performed. IV&V will keep the criticality rating for this category Green		
G	G	G	Organizational Maturity Assessment (OMA)	IV&V will be conducting an OMA with BHA on April 4, 2022. The results of the OMA will be shared in the April status report. The criticality rating for the OMA category remains Green (low).		
Y	Y	R	Quality issues continue to persist as there were several R3.22 post-production defects that will be addressed at the formal RCA in early April. 'Big Boulder' prioritized features/functionality implementation schedules continued to slip during March largely due to dependencies working directly with multiple third-party entities. The transition of a core deployment team member will impact the Phase 3 velocity. As a result, IV&V has escalated the criticality for this category to a Red (high) for the month of March.			



Executive Summary

As of the March 2022 reporting period, there are a total of seven (7) open findings – two High Issue, four Medium Issues, and one Low Issue spread across the Sprint Planning, Release / Deployment Planning, Test Practice Validation, and Project Management assessment areas.





Assessment Categories

Throughout this project, IV&V verifies and validates activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transfer (KT) Sessions
- Targeted Knowledge Transfer (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management



IV&V Findings & Recommendations Sprint Planning

#	Key Findings	Criticality Rating
7	High Issue - The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity. The new ITS4 started on 3/1/2022 as planned and has been assigned to the automated regression testing effort. Observations regarding resource constraints identified in December remain generally the same: 1) The BHA Solution Architect is on leave from early January through early April 2) A key BHA deployment team member is approximately 50% allocated to a significant CAMHD/MedQuest rate change initiative starting in May, and 3) DDD's IT/Security resource retired at the end of December. DDD is still awaiting approval authority to post its open IT position and the responsibilities for this position are currently being covered by an existing DDD team member. IV&V remains very concerned with these resource issues and will continue to closely monitor this high criticality issue. The lack of documentation continued to make it difficult for BHA developers to complete their assigned Calculator code assignments, as the Calculator code is difficult to navigate. Mitigation activities for the absence of Calculator 3.0 documentation to aid with development occurred on March 24 th which included a review of the inline comments within the code via a Knowledge Transfer Session with RSM and the assigned BHA resource. A request was added to DevOPS for the time necessary to develop Calculator 3.0 documentation but has not been prioritized due to budget constraints. In March, a decision was made to transition a DDD technical resource supporting deployments to focus primarily on Power BI reports. As a result of this unplanned resource change, the current deployment support work is put further at risk. The project has estimated this transition will impact approximately 30% of the planned configuration and development velocity over the next 2-3 releases, directly affecting the priority features in the latest roadmap. IV&V will continue to monitor how this new development affects the contin	H



IV&V Findings & Recommendations Sprint Planning (cont'd)

Recommendations	Status
BHA needs, and should pursue, additional Knowledge Transfer sessions on the updated Calculator 3.0 solution. Knowledge Transfer sessions should include complete documentation of the solution.	In progress
The Project should investigate mechanisms of increasing the bandwidth of the BHA Technical Team, either by adding resources through new hires, or vendor contracts.	In progress
The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff.	In progress
The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability.	In progress
The Project should consider the formation of a first level resource team to triage/address production defects in a timely manner, without disrupting new development work.	Completed
The Project should consider procurement of an online training toolset to support OCM and technical efforts to offset the need for in-person training.	Completed



Test Practice Validation

#	Key Findings	Criticality Rating
2	Medium Issue – As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment. R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were critical, one was high, and remaining two were medium defects. A Mid Sprint Deployment was deployed on 3/31/2022 to fix the critical and high defects and replace a deprecated Dataverse connector. An initial RCA assessment was performed on the R3.22 defects on 3/24/2022 and a formal RCA is being planned for early April. It is currently unclear if these issues were caused by software defects, testing, promotional issues, network issues, MDM issues, or other issues. BHA has commenced planning for the implementation of automated regression testing and has documented requirements to aid in the evaluation of an automation test tool. Additional automation test tool demonstrations have been scheduled and BHA anticipates to select a tool within the month of April or May. The regression test automation effort is currently anticipated to last 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue.	M

Recommendations	Status
 Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. 	In progress
 IV&V recommends DDD and CAMHD develop a common and consistent approach across divisions for regression testing. 	Completed



IV&V Findings & Recommendations Test Practice Validation (cont'd)

Modifying the deployment scripts based on information gained from previous release deployments.	 Implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. 	 Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute. (This recommendation was for a point in time and is no longer valid.) 	 Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to FSU releases. In addition, consider alternating the DDD and CAMHD scripts every other release. 	 Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. 	 Modifying release schedules to allow for regression testing timeframes. 	 Updating the regression test scripts to ensure consistency with system configuration. 	 Determine if current regression testing timeframes are adequate and if not, add more time to the pre- production regression test efforts for all release deployments. 	Recommendations
Completed	Completed	Completed	Completed	Completed	Completed	Completed	Completed	Status



Test Practice Validation (cont'd)

Recommendations	Status
Consulting with RSM to determine how the 'interim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing.	Completed
 IV&V recommends performing an RCA in collaboration with RSM for the continued concerns with regression testing efforts. 	Completed



Release / Deployment Planning

#	Key Findings	Criticality Rating
18	Medium Issue - Due to ongoing deployment processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments. R3.22 was promoted to production on 3/17/2022. There were reports of five (5) defects resulting from this deployment. Two were critical, one was high, and two were medium defects. A Mid Sprint Deployment was deployed on 3/31/2022 to fix critical and high defects and replace a deprecated Dataverse connector. An initial RCA assessment was performed on the R3.22 defects on 3/24/2022 and a formal RCA is being planned for early April. It is currently unclear if these issues were caused by software defects, testing, promotional issues, network issues, MDM issues, or other issues. IV&V notes that the Full Solution Upgrade for R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all production promotions.	M

Recommendations	Status
 Ensure there are adequate and qualified resources to support the current deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 	In Progress
As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	In Progress



Release / Deployment Planning (cont'd)

Recommendations	Status
 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. 	In Progress
Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities.	In Progress
The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls.	In Progress
IV&V recommends performing an RCA in collaboration with RSM for the continued concerns surrounding environment differences.	In Progress
• IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH.	In Progress
Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	Completed
Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production.	Completed
 Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. 	Completed



Release / Deployment Planning (cont'd)

Recommendations	Status
 Develop a plan to institutionalize the execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. 	Completed
• Due to an error prone process of 'cherry picking' what is and what is not ready for deployment, IV&V recommends that DOH and RSM collaborate to determine an improved manner for managing DOH environments. (As a result of how the current development environment is being managed, 'cherry picking' components to deploy will continue to occur. This recommendation is closed.)	Closed



Project Management

#	Key Findings	Criticality Rating
14	Medium Issue - Due to multiple quality concerns, the Project may continue to face impactful system defects. The R3.22 release promoted to production on 3/17/2022 resulted in several quality issues to include two critical, one high, and two medium defects. A Mid Sprint Deployment on 3/31/2022 was needed to fix critical and high defects and replace a deprecated Dataverse connector. An initial RCA assessment was performed on the R3.22 defects on 3/24/2022 and a formal RCA is being planned for early April. It is currently unclear if these issues were caused by software defects, testing, promotional issues, network issues, MDM issues, or other issues. IV&V will continue to monitor the quality of work for this medium issue.	M

Recommendations	Status
Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	Open
Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	In Progress
Assign dedicated resources to provide oversight of CAMHD Fiscal Processes.	In Progress
Monitor implemented improvements for effectiveness.	In Progress

Recommendations	Status
 IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. 	Completed
BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality.	Completed
 Perform typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 	Completed
• Dedicate sufficient time in between releases for BHA and RSM to execute/implement RCA correction actions to reduce the volume of unplanned rework.	Completed

#	Key Findings					
12	Medium Issue – PII/PHI data in non-production environments. IV&V continues to note that a Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.					
Recommendations						
	V recommends DOH consider limiting the volume of environments with PII/PHI data and access essary to support development work, which should help minimize this risk.	Open				
	V recommends if production data is necessary in any non-production environment that DOH establishes a for effectively managing the security of the PII/PHI data, including the potential masking of data.	In Progress				
	V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated i-production environments.	In Progress				

#	Key Findings	Criticality Rating
21	Low Issue – Unplanned rework may have an impact on delivering DDI functionality by the end of the DDI period. The defect percentage (25%) in March was higher than February but remained close to the target of 20% or less of the USPs deployed to production. IV&V will continue to monitor this finding.	L

Recommendations	Status
Reduce the amount of unplanned rework by continuing to focus on quality improvement measures.	In Progress
Strive for defect performance metric not to exceed 20% of all user story points in any given release.	In Progress



#	Key Findings				
	Change from Low Issue to High Issue – The project schedules for 'big boulder' interfaces functionality development are slipping. 'Big Boulder' prioritized features/functionality implementation schedules continued to slide and change priority during March, largely due to dependencies working directly with multiple third-party entities (HSRI, CAFAS, HHIE ADT, eRX). It is projected that some of the 'Big Boulder' items will not be implemented by the end of the DDI period. The Project's updated Draft Feature Roadmap currently includes the following:				
	 R3.23 (4/28/2022) - Golden Record Project, DDD Provider Portal, Rollout, CAMHD Customer Portal MVP, Transition Billing Process to INSPIRE, MQD Rate Change, IMHE Power App, Automated Testing, Dashboards and Reports 				
	 R3.24 (6/9/2022) - CAMHD Customer Portal MVP, MQD Eligibility Interface, Advanced Analytics Project, CAMHD Provider APIs, CAFAS Interface, Automated Testing, and Dashboards and Reports 	A			
22	 R3.25 (7/21/2022) - Advanced Analytics Project, ePrescribe, CAMHD Provider API's, CAFAS Interface, Automated Testing, and Dashboards and Reports 				
	 R3.26 (9/1/2022) - Advanced Analytics Project, ePrescribe, HHIE ADT Interface, Automated Testing, Dashboards and reports, and Federal FHIR Compliance. 				
	 R3.27 (10/13/2022) - Advanced Analytics Project, ePrescribe, HHIE ADT Interface, Dashboards and Reports, and Federal FHIR Compliance. 				
	• R3.28 (12/01/2022) - Dashboards and Reports.				
	Due to the continued slippage of the 'Big Boulder' schedules and the velocity impacts caused by the transition of a core deployment team member, IV&V has changed the criticality of this finding from a low issue to a high issue. We will continue to closely monitor this issue and the status of the 'Big Boulder' initiatives.				

Recommendations	Status
 Extend the current DDI timeframe to allow for the completion of 'big boulder' interfaces functionality development. 	In Progress
BHA to add more resources to support the development of "big boulder' interfaces functionality.	Open



Project Performance Metrics

Metric	Description	IV&V Observations	IV&V Updates			
Velocity	 Review and validate the velocity data as reported by the project Verify the project is on pace to hit the total target number of US/USP for Phase 3 	March - Available velocity was estimated at 161 user story points for R3.22 and a total of 163 user story points were promoted to production on 3/17/2022. The overall cumulative Phase 3 targeted USP's through R3.22 was planned for 1,855, and the actual USP count is now 2,458.27. Overall, this continues to exceed expectations for volume of work performed.	N/A			

Project Performance Metrics (cont'd.)

Metric Description		IV&V Observations	IV&V Updates				
Defect Metrics	Understand and track the following: • Defects by category (bug fixes) • US Points assigned to defects in a release vs US Points assigned to planned US in a release	 March – R3.22 was deployed to production on March 17, 2022. A total of 163 USPs were promoted to production. 75% of the total USPs were associated with planned user stories and requests. 25% of the total USPs were associated with defects that were either encountered during the release or pulled from the backlog. The defect ratio in March was close to the Projects' target levels of being 20% or less of the total USPs in any given release. 	N/A				



Appendix A: IV&V Rating Scales

Appendix AIV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.


- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.



Schedule issues are emerging (> 30 days but < 60 days late).

Project Leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.

The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned.

Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

Criticality Rating	Definition
•	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
•	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.

Appendix B: Inputs

Appendix B

Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the March 2022 reporting period:

- Daily Scrum Meetings (selected)
- 2. Twice Weekly RSM Issues Meeting
- 3. Weekly BHA-ITS Project Status Meeting
- 4. Bi-Weekly Check-in: CAMHD
- 5. Bi-Weekly Check-in: DDD
- 6. BHA IAPDU Planning Meeting
- IV&V Draft IV&V Status Review Meeting with DOH
- 8. IV&V Draft IV&V Status Review Meeting with RSM and DOH

Eclipse IV&V® Base Standards and Checklists

Artifacts reviewed during the March 2022 reporting period:

- Daily Scrum Notes (selected)
- 2. Twice Weekly Issues Meeting Notes (selected)
- 3. Automation Test Tool Requirements



Appendix C: Project Trends

Appendix C Project Trends

Trend: Overall Project Health										
Process Area		2021/2022								
Process Area	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
User Story Validation										
Test Practice Validation										
Sprint Planning										
Release / Deployment Planning										
OJT and KT Sessions										
Targeted KT										
Project Performance Metrics										
Organizational Maturity Metrics										
General Project Management										
Total Open Findings	8	10	8	8	9	8	8	8	7	7
Issue - high	4	4	2	1	2	1	1	1	1	1
Issue - medium	2	2	3	4	4	4	4	4	4	4
Issue - low	1	1	0	0	3	3	3	3	2	2
Risk - high	0	0	0	0	0	0	0	0	0	0
Risk - medium	0	0	0	0	0	0	0	0	0	0
Risk - low	0	0	0	0	0	0	0	0	0	0
Preliminary Concern	1	3	3	3	0	0	0	0	0	0





Solutions that Matter

ID	Date Identified	Finding	Finding Statement	Supporting Analysis	PCG Recommendation	Finding Update	Process Area	Finding Type	Priority	Status	Risk Owner	Closure Reason
1	12/31/2019	Detailed investigation into the project's sprint planning processes and adoption of generally accepted agile best practices.	IV&V is currently investigating the following topics as they relate to Sprint Planning and the project's overall approach to agile software development: - IV&V acknowledges that the project is now planning three sprints outs, however, it appears that only a "highlevel" sprint planning roadmap has been produced, and it is unclear exactly how the project is targeting features for each release through the end of Mod 4 IV&V is not aware of how the project is currently defining "done" for Mod 3 and Mod 4Additionally, in the January 2020 reporting period, IV&V will seek additional information and visibility into the project's processes specific to prioritizing requests and how user stories in TFS are tagged to		As much as possible, the project should identify what feature enhancements will be targeted for each Release and should clearly map out the roadmap out through the last Phase 3 release in September 2020.Additionally, the project should clearly define "Done" to ensure the project team is working towards the same goal and increase opportunities for success. Having a clear "definition of done" will help provide the project with guidance on how to stay within scope.	01/31/2020 - IV&V is closing this concern, and will be tracking items related to Definition of Done, roadmap, resourcing, and backlog grooming in new, separate findings.	Sprint Planning	Preliminary Concern	N/A	Closed	Ramesh, Vijaya (PCG)	Due to multiple new items being tracked at a more granular level, this item has been closed.
2	12/31/2019	As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment.	deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD	Thorough vetting and validation of regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the problem.	in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. IV&V recommends DDD and CAMHD to develop a common and consistent approach across divisions for performing regression testing. Determine if current regression testing timeframes are adequate and if not, add more time to the pre-production regression test efforts for all release deployments. Updating the regression test scripts to ensure consistency with system configuration. Modifying release schedules to allow for regression testing timeframes Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution.	03/31/2022 - R3.22 was promoted to production on 3/17/2022. There were five (5) defects resulting from this deployment. Two were critical, one was high, and remaining two were medium defects. A Mid Sprint Deployment was deployed on 3/31/2022 to fix the critical and high defects and replace a deprecated Dataverse connector. An initial RCA assessment was performed on the R3.22 defects on 3/24/2022 and a formal RCA is being planned for early April. It is currently unclear if these issues were caused by software defects, testing, promotional issues, network issues, MDM issues, or other issues. BHA has commenced planning for the implementation of automated regression testing and has documented requirements to aid in the evaluation of an automation test tool. Additional automation test tool demonstrations have been scheduled and BHA anticipates to select a tool within the month of April or May. The regression test automation effort is currently anticipated to last 2-3 months for the initial setup. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - R3.21 was promoted to production on 2/3/2022. There were reports of	Test Practice Validation	Issue	Medium	Open	Darren Macdonald	

2 42/2/2015	I	In and the second	I	I	T / / :	L	I	I.	la	la	1
3 12/31/2019	Usage of open source JavaScript	IV&V learned in December	Open source tools and frameworks offer	IV&V recommends BHA work to	08/31/2020 - IV&V is unaware of any additional	Targeted KT	Risk	Low	Closed	Darren Macdonald	RSM has successfully
	framework for development and	2019 that the Calculator 3.0	organizations great opportunities to build	'	KT gaps being identified by DOH, and as such, is						held several KT
	7 7	functionality is built in	and configure customized solutions at	process for keeping abreast of	closing this finding.07/31/2020 - The Project						sessions for this
	3.0 requires BHA to take a proactive		lower costs than through software	communal updates and support	resolved the majority of the outstanding						technology and
	approach to support and security.		purchase or licensing. However, open	opportunities for a new suite of	Calculator 3.0 defects during July which was						functionality, and
		framework is relatively new,	source tools and frameworks often do not	· ·	implemented in the mid-sprint release on						DOH staff have
		the open source support	come with support models, other than		7/17/2020. The final Calculator 3.0 Knowledge						stated that it was
		community is small. IV&V's	those offered through the tool's	targeted KT sessions with RSM on	Transfer session was conducted on 7/17/2020.						well received.
		concerns include: - The	community. Because of this, the	maintaining Calculator 3.0 via a	IV&V recommends BHA to identify and						
		availability of reliable	organization bears the weight of seeking	suite of tools, and determine what							
		support for Vue.JS - The	out reliable help and support, as well as	additional skillsets, training,	during the month of August. If no additional						
		project's understanding of	much take a proactive approach to	and/or resources are needed to	needs are identified, IV&V will close this						
		any known vulnerabilities	security and identifying any vulnerabilities	_ · ·	finding. 06/30/2020 - The project continued to						
		with Vue.JS, and	in the tools.	ownership of Calculator 3.0 -	focus attention on the Calculator 3.0 defects						
		development of a process to		Completed	during the month of June. RSM conducted						
		remain current on			another Calculator 3.0 Knowledge Transfer						
		vulnerabilities discovered by			session on 6/26/2020 and scheduled a final						
		the support community			session for 7/17/2020. 05/31/2020 - The						
		The RSM lead for Calculator			project continued to focus attention on the						
		3.0 went on extended			Calculator 3.0 user stories and defects during						
		parental leave in December			the month of May. RSM conducted another						
		2019IV&V acknowledges that			Calculator 3.0 Knowledge Transfer session on						
		BHA has downloaded Vue.JS			5/29/2020 which IV&V attended. This session						
		to start getting familiar with			included the new C3.0 year-end changes.						
		it.			Additional KT sessions is planned for and IV&V						
					will continue to monitor this project						
					component during June. 04/30/2020 - The						
4 1/31/2020	Due to the project not following a	There have been several	A complete, up to date, and documented	IVV recommends documenting	12/31/2020 - IV&V has closed this issue as the	Release/Deploy	Issue	Medium	Closed	Darren Macdonald	Key finding has been
4 1/31/2020	detailed deployment script, the	defects pushed to	deployment script is needed to ensure the	deployment scripts for both the	12/31/2020 - IV&V has closed this issue as the related recommendations below has been	Release/Deploy ment Planning	Issue	Medium	Closed	Darren Macdonald	addressed and
4 1/31/2020	detailed deployment script, the project may continue to experience	defects pushed to production with Phase 3	deployment script is needed to ensure the repeatability and stability of DOH's	deployment scripts for both the patch method and the full solution	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are	deployment scripts for both the patch method and the full solution upgrade method. The script(s)	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations
4 1/31/2020	detailed deployment script, the project may continue to experience	defects pushed to production with Phase 3 releases. Some of the defects introduced to production	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020.		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances,	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard.	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to develop a detailed Production Deployment		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution
4 1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment	defects pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to	deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place.	deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-bystep procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and	12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to		Issue	Medium	Closed	Darren Macdonald	addressed and proposed IV&V recommendations have been completed. A subsequent finding #19 has been created to address on-going deployment processes and technical execution

5	1/31/2020	challenge the project's ability to fully achieve the goals of Phase 3.	100 User Stories of for Phase 3. Because of this, it is unclear how proposed functionality/features are prioritized for each sprint, and throughout Phase 3.	The 'Definition of Done" document guides the Project's vision, business, and technical goals that are important inputs for stakeholders to develop a Roadmap for Phase 3. Without the 'Definition of Done' document, the project is likely to struggle to prioritize proposed functionality/features which may be equally important but are at odds with each other.	of creating the Definition of Done. IV&V recommends that the project create this document and socialize this with project team before end of Feb 2020IV&V recommends that the project consider the items from the prioritized list, available resources and define "Done" as a percentage of the identified priority list with room for flexibility to add any other features/enhancements that will be identified during Phase 3.		Project Management	Concern	N/A	Closed		Definition of Done completed and socialized.
6	1/31/2020	The lack of consistent backlog grooming could result in the project backlog having obsolete, non-estimated, and poorly defined user stories.	continues to grow. Currently,		IVV recommends that CAMHD and DDD groom the backlog to bring it as current and accurate as possible. This should include deprecating items no longer needed, and fully defining those items that are not yet fully defined, readying them for configuration or developer resources. To the extent feasible, BHA should involve RSM SMEs in this process, if only for the interim to get "caught up" on grooming efforts. (Closed)VV recommends that the project consider utilizing an age-based methodology for the deprecation of 'older' user stories in the backlog that may no longer be applicable or needed by the Product Owners and developing a process for periodic cleansing of the backlog using the same methodology. (Closed)	06/30/2020 - IV&V has observed for another month that the project continues to groom the backlog. As a result, we are closing this finding.05/31/2020 - The project team has determined the backlog grooming effort has caught up, as details for release 3.9 are completed and 3.10 is near completion. IV&V will keep this finding open for an additional month to validate that the backlog continues to be groomed as new stories and defects are identified. Efforts to keep the backlog groomed should take place each month so that release planning efforts are not delayed. 04/30/2020 - The project reported that 97% of the original backlog has been estimated at this time. That said, CAMHD has determined that there are several older, and possibly no longer necessary user stories in the backlog that are candidates for deletion. IV&V will keep this finding open and will re-assess it for impact during the month of May.03/31/2020 - IV&V validates that the backlog grooming effort has made great progress, however it is still in progress. The revised target date for completion was most recently 3/31/2020. The estimation effort has reached 94% completion at the end of March and this includes new requests that have come	Project Management	Risk	Low	Closed	Darren Macdonald	The project has demonstrated they are consistently grooming the backlog.

-					1								
	7	1/31/2020	The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity.			1	03/31/2022 - The new ITS4 started on 3/1/2022 as planned and has been assigned to the automated regression testing effort. Observations regarding resource constraints identified in December remain generally the same: 1) The BHA Solution Architect is on leave from early January through early April 2) A key BHA deployment team member is approximately 50% allocated to a significant CAMHD/MedQuest rate change initiative starting in May, and 3) DDD's IT/Security resource retired at the end of December. DDD is still awaiting approval authority to post its open IT position and the responsibilities for this position are currently being covered by an existing DDD team member. IV&V remains very concerned with these resource issues and will continue to closely monitor this high criticality issue. The lack of documentation continued to make it difficult for BHA developers to complete their assigned Calculator code assignments, as the Calculator code is difficult to navigate. Mitigation activities for the absence of Calculator 3.0 documentation to aid with development occurred on March 24th which included a review of the inline comments	Sprint Planning	Issue	High	Open	Darren Macdonald	
8	3 :	1/31/2020	the near term (next 3 months), midterm, and long term could have	definitive Product Roadmap for Phase 3 that addresses the functionalities, features, and / or enhancements to be	A Roadmap is a tool that guides an agile project on what functionalities/features are targeted to be built and released and when users can have access to these functionalities. Without a defined Roadmap the project may not be able to effectively scope the top features to be released within Phase 3 and ensure the correct resources are available to accomplish the goal of each sprint and the Phase.	IV&V understands that the Project is in the process of creating a Short Term; Mid Term, and Long Term Roadmap. IV&V recommends the Project complete this by the end of February 2020 to understand if there are any constraints (resources, budget) that may hinder the project from releasing the needed functionalities/features targeted for Phase 3 as documented in the Definition of Done.	02/29/2020 - In February, the project further defined the Phase 3 Product Roadmap and aligned it with the Phase 3 Definition of Done. IV&V recommends the project continually review and update both the Product Roadmap and Definition of Done, adjusting as necessary. IV&V will continue to monitor the project's adherence to the Product Roadmap and progress against it but is closing out this concern as of the February report.	Project Management	Preliminary Concern	N/A	Closed		Product Roadmap aligned with Definition of Done

9	3/31/2020	related "stay at home" order could hinder project activities and negatively impact the project schedule and budget.	issued a "stay at home, work from home order" that has reduced state departments ability to be fully functional as the large majority of state workers will be required to work from home/remotely at least until the end of April and some offices may be completely shut down until that time as well. Unclear if	DOH stakeholder participation in key activities could be significantly hindered, not only by required remote work by DOH and SI staff, but also by the flood of activities that could occur as the department could become overwhelmed processing and providing services due to the resulting economic impacts to citizens. Some stakeholders may be unable (due to stricter shutdown policies) or unwilling to perform these activities during this chaotic time. Planned SI onsite visits will also likely be changed to remote which could reduce the effectiveness of their project activities. Going forward most if not all project activities will more than likely be conducted remotely until this crisis passes.	work devices and tools and make every effort to help them to become highly functional with remote access technology (e.g. MSTeams/Skype) - Completed-IV&V recommends the project and DOH create a detailed, documented risk mitigation strategy and plan that is reviewed regularly and revised to address the current state of the COVID-19 threat and related impacts over the next 6 to 12 months - In Progress - IV&V recommends updates to the OCM Plan to include any new activities or	04/30/2021 - The Project continues to maintain its ability to operate with staff working remotely, effectively overcoming the "stay at home, work from home order" that reduced BHA's ability to be fully functional in the office. The potential DDD and CAMHD budget challenges reported in March were also overcome during April, providing fiscal relief to BHA. As such, IV&V is closing this finding.03/31/2021 - The Project continued to maintain its ability to operate with staff working remotely, while COVID-related responsibilities continue to grow for CAMHD Leadership. The Governor announced that potential furloughs and/or layoffs of State workers will no longer be necessary based on the signing of the American Rescue Plan. IV&V has reduced the priority of this finding from Medium to Low and will continue to monitor moving forward. 02/28/2021 - As reported in January, there were no substantive changes observed for this finding in February. The Project continued to maintain its ability to operate with staff working remotely. IV&V continues to note that there may be potential future budget actions by the Governor due to projected State budget shortfalls, including	Project Management	Risk	Low	Closed	Darren Macdonald	The Project continues to maintain its ability to operate with staff working remotely, effectively overcoming the "stay at home, work from home order" that reduced BHA's ability to be fully functional in the office. The potential DDD and CAMHD budget challenges reported in March were also overcome during April, providing fiscal relief to BHA.
10	5/31/2020	The lack of design reviews for complex user stories has resulted in the promotion of incomplete solutions into production.	the code promoted to	If all requirements within a functional design are not met, users could experience the inability to complete required processes, resulting in incomplete data collection and potential issues in service delivery.	IV&V recommends (and DOH has commenced) conducting technical design reviews for complex user stories prior to development to ensure designs are complete and all requirements associated with the design are met. IV&V observed this activity has been implemented by DOH in the month of May.	07/31/2020 - The Project continues to to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. This process change has proven successful, and as such, IV&V recommends closing this concern.06/30/2020 - IV&V acknowledges the Project Team continued to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. IV&V will continue to monitor in July.		Preliminary Concern	N/A	Closed		This process change to spend extra time on the design of complex user stories to ensure that all requirements are represented has proven to be successful.

11	7/31/2020	DDD Project resource shortages	The user adoption and	The significance and impact of OCM can	IV&V recommends that BHA does	03/31/2021 - The DDD staff who've been part	Project	Risk	N/A	Closed	Darren Macdonald	The DDD staff
		may have a continued negative	training efforts are	never be understated. It is clearly a best	as much as possible within its	of the review process are pleased with the	Management					who've been part of
		effect on user adoption, training,	hampered based on staffing	practice that best that all staff utilize the	sphere of influence to increase	quality of the videos produced within the						the review process
		and overall OCM activities.	shortages. DDD has stated	solution in the same manner. Variations	user adoption and training. This	toolset and have determined that the toolset is						are pleased with the
			that its users have been	in how the system is utilized by its users is		a very helpful training tool for DDD staff and						quality of the videos
			found to not be utilizing the	likely to cause variations in data collection		providers. As such, IV&V is closing this						produced within the
			system to its fullest extent in	and analytical efforts using the data	the need for in-person training,	finding.02/28/2021 - Training videos using the						toolset, and have
			terms of system workflow,	collected.	and adding staff as needed to	new toolset were nearing completion by the						determined that the
			provide their insights and		support OCM and technical	end of February. DOH is currently reviewing the						toolset is a very
			input, follow up, etc. To assist in OCM activities, DDD		efforts. IV&V recommends DOH	drafts of the second set of videos and work is progressing well. IV&V will continue to monitor						helpful training tool for DDD staff and
			has defined the need for an		the specific variations as to how	this finding until DDD has had sufficient time to						providers.
			interactive training tool to		the system is currently being used	determine the overall quality of the training						providers.
			support Inspire.		by the user community.	work products and whether the new toolset is						
			зарроге пізріге.		Consequently, users would be	addressing user adoption and staffing						
					provided with constructive	shortages for these task efforts. 01/31/2021 -						
					feedback on how the system	Training design activities using the interactive						
					should be utilized where gaps	training toolset commenced in January and has						
					exist. This will likely lead to	attained good progress. The use of this tool is						
					additional refresher training to	expected to provide some bandwidth relief for						
					close identified system knowledge	· ·						
					gaps.	new staff members and providers, and to						
						provide refresher training to existing staff						
						members. IV&V will continue to monitor this						
						finding12/31/2020 - The contract to procure						
						the interactive training toolset for onboarding						
						new staff members and providers and to						
12	0/24/2020		-									
	8/31/2020	PII/PHI data in non-production	IV&V has been made aware	Failure to secure PII/PHI data leaves the	IV&V recommends DOH consider	03/31/2022 - IV&V continues to note that a	Project	Issue	Medium	Open	Darren Macdonald	
	8/31/2020	PII/PHI data in non-production environments	IV&V has been made aware that PII/PHI data currently	Failure to secure PII/PHI data leaves the organization open to highly targeted	IV&V recommends DOH consider limiting the volume of	03/31/2022 - IV&V continues to note that a Security Assessment is planned for the second	Project Management	Issue	Medium	Open	Darren Macdonald	
	8/31/2020			· ·				Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently	organization open to highly targeted	limiting the volume of	Security Assessment is planned for the second		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project	organization open to highly targeted social engineering attacks, heavy	limiting the volume of environments with PII/PHI data	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk.	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue.		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data.	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue.		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V continues to note that a Security Assessment is		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue.		Issue	Medium	Open	Darren Macdonald	
	8/31/2020		that PII/PHI data currently exist in a non-production environment to meet project needs. Generally this is not a good security practice as the presence of PII/PHI data in non-production environments increases the potential for theft, loss or exposure thus increasing the organization's risk. Failure to secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of	organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust	limiting the volume of environments with PII/PHI data and access necessary to support development work, which should help minimize this risk. IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production	Security Assessment is planned for the second quarter of 2022, which will likely require BHA to act on this finding in May or June 2022. IV&V notes that some of the automated regression tools being evaluated include data masking capabilities which will help to mitigate this issue. IV&V will continue to monitor this medium criticality issue. 02/28/2022 - The effort to address this issue remains on hold until additional staff are available. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V will continue to monitor this medium criticality issue. 01/31/2022 - There were no substantive changes to this finding in January. This effort continues to remain on hold until additional staff are available to address this issue. IV&V continues to note that a Security Assessment is planned for the first quarter of 2022, which will likely require BHA to act on this finding. IV&V		Issue	Medium	Open	Darren Macdonald	

13	8/31/2020	Project not able to access Activity	The Project recently	The unavailability of activity logs may	IV&V recommends that DHS	03/31/2021 - Per BHA, this finding is no longer	Release/Deploy	Risk	N/A	Closed	Darren Macdonald	Finding has been
13	8/31/2020	Logs	deployed audit log	hamper the investigation of future	continues to collaborate with	an issue and recommends closure. IV&V is	ment Planning	NISK	IN/A	Cioseu	Darren Macdonald	resolved.
		Logs	functionality into production	'	Microsoft until the activity logging	closing this finding.02/28/2021 - BHA	inent Flaming					lesoiveu.
			whereby these logs can be	security breaches.	feature is available in all BHA non-	continued this effort in February despite a						
			accessed and exported as		production environments.	workaround being necessary from Microsoft						
			needed. However, IV&V was		production environments.	due to a layering issue. Based on continued						
			made aware access to			delays, it is unclear when this important						
			activity logging for users with			security activity will be completed. IV&V will						
			just view permissions will not			continue to monitor this finding. (Per Kamu,						
			be available from Microsoft			this status information did not correctly reflect						
			in the public sector			the issue as the layering issue has no relation to						
			environment until the end of			the activity logs.)01/31/2021 - The						
			September 2020. The			implementation effort for this activity moved						
			unavailability of these			forward in January. Some of the entities will						
			specific activity logs could			have activity logging completed in the planned						
			potentially hamper the			early February Release 3.12, while others will						
			investigation of future			be delayed until Release 3.13. IVV will continue						
			security events until			to monitor. 12/31/2020 - The planning effort						
			implemented.			for identifying the entities that will require						
			'			activation of the new activity logs was						
						completed during December. The						
						implementation effort has been prioritized for						
						inclusion in Release 3.12. IV&V will continue to						
						monitor this finding until implemented.						
						11/30/2020 - The DOH technical team has						
						commenced the analytical effort to determine						
						which entities to activate the logging features						
14	9/30/2020	Due to multiple quality concerns,	System defects identified in	The identified quality issues have	Evaluate existing project staff skills	03/31/2022 - The R3.22 release promoted to	Project	Issue	Medium	Open	Darren Macdonald	
		the project may continue to face	August that affected claims	negatively affected DOH billing processes	and experience level to ensure	production on 3/17/2022 resulted in several	Management					
		impactful system defects.	were due to multi-faceted	and DOH has stated these are the most	they meet BHA support	quality issues to include two critical, one high,						
			quality issues were	impactful defects discovered to date.	requirements.	and two medium defects. A Mid Sprint						
			individually addressed during	:	Perform revenue neutrality fiscal	Deployment on 3/31/2022 was needed to fix						
			this reporting period. IV&V		balance testing on a quarterly	critical and high defects and replace a						
			notes that there is one		basis to ensure revenues are as	deprecated Dataverse connector. An initial RCA						
			remaining defect still being		expected.	assessment was performed on the R3.22						
			evaluated that affects a		Assign dedicated resources to	defects on 3/24/2022 and a formal RCA is being						
			limited number of claims.		provide oversight of CAMHD Fiscal	planned for early April. It is currently unclear if						
			Overall, the Project Team has		Processes.	these issues were caused by software defects,						
			responded with a		Monitor implemented	testing, promotional issues, network issues,						
			commitment to increase		improvements for effectiveness.	MDM issues, or other issues. IV&V will						
			project quality and is in the		IV&V recommends performing an	continue to monitor the quality of work for this						
			process of identifying		RCA in collaboration with RSM	medium issue.						
			improvements to associated		after all future release	02/28/2022 - R3.21 was promoted to						
			testing processes. These		deployments for continual quality	production on 2/3/2022. There were reports of						
			currently include:Performing		improvement.	nine (9) defects associated with this release,						
			Revenue Neutrality Testing		BHA and RSM to collaborate on	one of which was Critical and required a Mid-						
			to ensure expected revenue		the necessary revisions to the	Sprint Deployment the next business day. The						
			streams are largely		submitted design deliverables to	Project continues to adhere to established RCA						
			unchanged from one period		increase level of detail and quality.	procedures and performed an RCA for R3.21						
			to the next. Conducting		Perform typical project testing	where several suggestions for improvement						
			System Integration Testing,		Including System Integration, User	were identified. IV&V will continue to monitor						
			User Acceptance Testing,		Acceptance, Performance, and	this medium criticality issue.						
			Performance Testing, and Regression Testing for		Regression Testing. Dedicate sufficient time in	01/31/2022 - No new releases were planned for January but R3.21 release is anticipated to						
1	1	i	LiveRicosion Learning Ion		Dedicate sufficient time in	Inor samuary but no.21 release is anticipated to	I	l	1	1	1	1

4.5	1.0 /5 /0.000	I	I=	I= 6 11	I= a	I	L	I=	In. / a	la ı	In	I_, ,
15	10/5/2020	Usage of Semantics and IDM for	- 1 - 3	Default	Default	01/31/2021 - The project has made great	Targeted KT	Preliminary	N/A	Closed	Darren Macdonald	The project has
		development and ongoing	to obtain more targeted			strides addressing this concern. A Semantics		Concern				made good progress
		maintenance of the system requires				Layer KT session was conducted on 1/29/21						establishing and
		BHA to take a proactive approach	the Semantics Reporting and IDM tools. IV&V will continue			and multiple IDM and Semantic Layer sessions						initial execution of the IDM and
		to support of these tools.	to monitor this concern.			has been scheduled in February. IV&V is closing						Semantics Layer KT
			to monitor this concern.			this finding as we no longer view this item as a						· ·
						concern.12/31/2020 - IV&V is aware that an						plan.
						overview of the Semantics Layer KT session was						
						held on 12/16/20. The planning effort will						
						result in additional Semantic Layer and IDM KT sessions in the coming months. IV&V will						
						continue to monitor this finding.11/30/2020 -						
						The project conducted two high-level overview sessions of the Semantic Layer Reporting tools						
						during November. One session was focused on						
						the overall Semantic Layer, and the second						
						session was focused on Semantic Layer						
						Security. Additional targeted Knowledge						
						Transfer sessions on the Semantic Layer tools						
						will need to be provided by RSM; however,						
						these have not been scheduled. IV&V will						
						continue to monitor this finding.10/31/2020 -						
						The project intends to obtain more targeted						
						knowledge transfer for both the Semantics						
						Reporting and IDM tools and will be planning						
						and scheduling these sessions with the RSM						
16	10/27/2020	The handwidth of CANALD	CAMUD has been provided	CAMPH Loadership participation in key	IVEV recommends CAMHD look	team in the near future. IV&V will continue to	Droinet	Diek	N/A	Closed	Darron Macdonald	CAMUD Loadorchia
16	10/27/2020	The bandwidth of CAMHD	CAMHD has been provided	CAMDH Leadership participation in key	IV&V recommends CAMHD look	06/30/2021 - As anticipated, the CAMHD	Project Management	Risk	N/A	Closed	Darren Macdonald	CAMHD Leadership
16	10/27/2020	Leadership is being hampered by	with an approval to	activities could be significantly hindered	for opportunities to augment the	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has	Project Management	Risk	N/A	Closed	Darren Macdonald	time dedicated to
16	10/27/2020	Leadership is being hampered by planning tasks and activities for	with an approval to commence planning efforts	activities could be significantly hindered by the flood of activities that could occur	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 -		Risk	N/A	Closed	Darren Macdonald	time dedicated to
16	10/27/2020	Leadership is being hampered by planning tasks and activities for	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH.	activities could be significantly hindered by the flood of activities that could occur	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month.		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month.		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation,		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20%		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor. 04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be dedicated to the Vaccine		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be dedicated to the Vaccine Registration Project, instead of BHA resources IV&V will continue to monitor this		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has
16	10/27/2020	Leadership is being hampered by planning tasks and activities for assessing project expansion to	with an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this	activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of	for opportunities to augment the management staffing for planning	06/30/2021 - As anticipated, the CAMHD Leadership time dedicated to the Project has returned to normal and expected levels. As such, IV&V is closing this finding. 05/31/2021 - As anticipated, CAMHD Leadership time spent on efforts outside of the Inspire Project reduced during May. This level of effort decreased to approximately 10% of available time in May, largely for the planning of the Max/Inspire divisional expansion effort. As such, IV&V is reducing the priority of this finding from Medium to Low and will continue to monitor.04/30/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during early April but has decreased at the end of the month. Approximately 60-70% of Leadership time was spent on Phase 4 Planning, COVID Remediation, and the new Vaccine Registration application efforts. The CAMHD level of effort is anticipated to decrease to approximately 20% in May as DOH has hired a Project Manager in April who will be dedicated to the Vaccine Registration Project, instead of BHA resources		Risk	N/A	Closed	Darren Macdonald	time dedicated to the project has

477	14 /20 /2020	I	I-1 1	I= 6 1:	In an in the second		l- , <i>,</i>	1.	1	la 1	la 14 1 11	<u> </u>
17	11/30/2020	Due to consistent technical issues	· ·	Default	IV&V recommends the project to	08/31/2021 -The number of issues requiring	Release/Deploy	Issue	N/A	Closed	Darren Macdonald	The volume of
		requiring escalation to Microsoft,	efforts have experienced		continue to monitor the status of	assistance from Microsoft continues to remain	ment Planning					interactions needed
		some project efforts are being	several delays attributable to		outstanding Microsoft tickets and	limited, and as such, IV&V is closing this						with Microsoft
		delayed.	issues escalated to		to escalate the priority of these	finding. 07/31/2021 - While the number of						remains low and
			Microsoft. The issues have		tickets as deemed necessary.	issues requiring assistance from Microsoft						manageable. This
			ranged from administrative /			remains limited, interactions with Microsoft are						condition is no
			communication (entering			increasing again due to the interface						longer impeding
			issues into the Commercial			functionality planned for implementation in the						project progress.
			support instance vs the			current and remaining DD&I releases. The FHIR						
			Government Cloud support			API interface has required multiple interactions						
			instance), to several key			with Microsoft that have resulted in unplanned						
			technical issues requiring			schedule slippages for the FHIR API						
			assistance to resolve. To			implementation. IV&V will continue to monitor						
			date, these support needs			this finding. 06/30/2021 - The number of issues						
			have added over a month to			requiring assistance from Microsoft continues						
			the IDM and Semantic Layer			to be low with only two known items open. As						
			project schedules.			such, IV&V is reducing the priority of this						
						finding to low and will continue to						
						monitor.05/31/2021 - There is only one open						
						Microsoft ticket affecting the attachment of						
						Claims to the Batch. As such, IV&V is reducing						
						the criticality of this finding from High to						
						Medium and will continue to monitor.						
						04/30/2021 - BHA continues to work with						
						Microsoft on technical issues as they arise in						
						the Government Community Cloud (GCC)						
						instance. The issue with fields being locked has						
18	12/31/2020	Due to an estandardament	There have been several	Described described advances and	Farmer there are a decrease and		Dalara /Daular	1	N 4 m of i comp	0	Darren Macdonald	
18	12/31/2020	Due to on-going deployment	There have been several	Repeatable documented release and	Ensure there are adequate and	03/31/2022 - R3.22 was promoted to	Release/Deploy	Issue	Medium	Open	Darren Macdonald	
		processes and technical execution	defects pushed to	deployment will help ensure that	qualified resources to support the	production on 3/17/2022. There were reports	ment Planning					
		issues, the Project may continue to	I'	mistakes are minimized, and that	current deployment processes.	of five (5) defects resulting from this						
		encounter defects and challenges in		functionality is not mistakenly deprecated	This may require the support from	deployment. Two were critical, one was high,						
		meeting projected timelines for	introduced to production	when deployments take place.	RSM resources to provide	and two were medium defects. A Mid Sprint						
		production and non-production	have been narrowed down to		assistance and knowledge transfer	Deployment was deployed on 3/31/2022 to fix						
		deployments.	environmental promotional		for some of the more complex	critical and high defects and replace a						
			activities. In these instances,		deployment components.	deprecated Dataverse connector. An initial RCA						
			the DEV and TEST		Work in collaboration with RSM to	assessment was performed on the R3.22						
			environments were not in		establish a transition plan for DOH	defects on 3/24/2022 and a formal RCA is being						
			sync with the production		to assume all deployment	planned for early April. It is currently unclear if						
			environment (missing		activities to ensure complete	these issues were caused by software defects,						
			business rules, missing		ownership of these processes. This	testing, promotional issues, network issues,		1				
			components, missing		should assist with consistency in	MDM issues, or other issues.						
	1	1	In a communication of the comm			i .	I	1	1	1		
1			dependencies, etc.). IVV is		approach and execution going	IV&V notes that the Full Solution Upgrade for						
			aware that DOH staff		approach and execution going forward.	IV&V notes that the Full Solution Upgrade for R3.22 was a very long event. The Project has						
			1 '			, -						
			aware that DOH staff		forward.	R3.22 was a very long event. The Project has						
			aware that DOH staff shadowed RSM staff for all		forward. As appropriate, consult with RSM	R3.22 was a very long event. The Project has identified options for remedying this situation						
			aware that DOH staff shadowed RSM staff for all deployment releases during		forward. As appropriate, consult with RSM on best practices that BHA could	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI)						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all production promotions.						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all production promotions. 2/28/2022 - R3.21 was promoted to production on 2/3/2022. There were reports of nine (9)						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all production promotions. 2/28/2022 - R3.21 was promoted to production on 2/3/2022. There were reports of nine (9) defects associated with this release, one of						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all production promotions. 2/28/2022 - R3.21 was promoted to production on 2/3/2022. There were reports of nine (9) defects associated with this release, one of which was Critical and required a Mid-Sprint						
			aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to		forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of	R3.22 was a very long event. The Project has identified options for remedying this situation to include: (1) perform an FSU every other deployment (2) have the System Integrator (SI) perform FSUs, and (3) have the SI perform all production promotions. 2/28/2022 - R3.21 was promoted to production on 2/3/2022. There were reports of nine (9) defects associated with this release, one of						

19	3/28/2021	The pending RSM contract expiration will require BHA to perform transition of the D365 solution to the State prior to contract end.	is currently planned to complete in September 2021. BHA will need a		Work hand in hand with RSM to ensure that DOH has the knowledge, skills, and capabilities to perform all aspects of the project prior to September 2021. If the knowledge transfer takes more time than planned, consider developing, testing, and promoting less releases in the summer months as the transition off of vendor support approaches.	05/31/2021 - Per CAMHD, the RSM contract amendments to extend the DD&I effort (Mod 5) to the end of December 2021 and also provide M&O services (Mod 6) through May 2022 were fully executed in May. IV&V is closing this preliminary concern. 04/30/2021 - The RSM contract amendment is still pending approval. This amendment will extend the DD&I effort (Mod 5) to the end of December 2021 and will also provide M&O services (Mod 6) through May 2022. Mod 5 is expected to be approved in May 2021. This will delay the near-term need for a Transition Plan until first quarter 2022. IV&V will continue to monitor this finding.	Project Management	Preliminary Concern	N/A	Closed	Vic Dudoit	The RSM amendments were fully executed in May 2021.
20	4/30/2021	The DDD Project Manager will be on leave and unavailable to the project starting in May.	duties on behalf of DDD and her absence may cause an increased level of risk to the project. DDD has	The DDD Project Manager is critical to all daily project interactions affecting DDD from a functional and managerial perspective. If her duties are not reassigned to capable staff prior to her planned absence, DDD will be in a challenged position to effectively contribute to at least the next several releases.	1) IV&V recommends DDD to continue to look for opportunities to augment the existing technical staff in order to fully support current DDI project work.2) IV&V recommends DDD to consider augmenting their current PM/Business staff in order to allow their technical staff to focus on technical duties.	08/31/2021 - The DDD Project Manager returned from her absence, alleviating the DDD technical staff bandwidth/workload challenges. IV&V is closing this finding.07/31/2021 - The DDD technical staff continued to face bandwidth/workload challenges during the month of July. Fortunately, the DDD Project Manager is scheduled to return to work on 8/2/2021 allowing the technical staff to return fully to their technical responsibilities.06/30/2021 - The absence of the DDD Project Manager continues to cause bandwidth/workload challenges for DDD technical staff. Time available for typical DDD CRM assignments was limited in June due to this resource constraint. IV&V has promoted this finding from a Preliminary Concern to a Medium criticality issue and will continue to monitor. 05/31/2021 - The highest priority tasks and activities typically accomplished by the DDD Project Manager have been reassigned to other DDD staff. IV&V notes that this results in some level of bandwidth/workload challenges for DDD technical staff.	Project Management	Issue	N/A	Closed	Darren Macdonald	The DDD Project Manager has returned from her leave, fully mitigating this issue.

24	C /22 /2224	I	I	I	I	Too to too or a life in the control of the control		1.	1.	l _o	la	
21	6/30/2021	Unplanned rework may have an	The continued volume of	Release defect metrics for unplanned	Reduce the amount of unplanned	03/31/2022 - The defect percentage (25%) in	Project	Issue	Low	Open	Darren Macdonald	
		impact on delivering DDI	unplanned rework may have	rework has been 30-40% of the total USPs	rework by continuing to focus on	March was higher than February but remained	Management					
		Functionality by the end of the DDI		for the last few releases.	quality improvement measures.	close to the target of 20% or less of the USPs						
		period.	planned DDI functionality		Strive for defect performance	deployed to production. IV&V will continue to						
			with only 4 possible DDI		metric not to exceed 20% of all	monitor this finding.						
			releases remaining for		user story points in any given	02/28/2022 - The percentage of defects versus						
			completion.		release.	planned user stories and requests continued to						
						improve during February. The defect						
						percentage (17%) in February was lower than it						
						has been in any of the previous 6 months and is						
						currently in alignment with the target of 20% or						
						less of the USPs deployed to production. IV&V						
						will continue to monitor this finding.						
						01/31/2022 - There were no substantive						
						changes to this finding in January. The						
						percentage of defects for R3.21 will be						
						available in February, when the release is						
						completed.						
						12/31/2021 - The percentage of defects vs						
						planned user stories and requests rose slightly						
						during December. The defect percentage was						
						29% in the December release which is close to						
						the target of ≤ 20% of the USPs deployed to						
						production. IV&V will continue to monitor this						
						low criticality issue.						
						11/30/2021 - The percentage of defects vs						
						planned user stories and requests continued to						
22	7/30/2021	The project schedules for 'big	The FHIR interface and	Weekly RSM Status Report	Extend the current DDI timeframe	03/31/2022 - 'Big Boulder' prioritized	Project	Issue	High	Open	Darren Macdonald	
		boulder' interface functionality	CAFAS interface are currently		to allow for the completion of 'big	features/functionality implementation	Management					
		development are slipping.	at risk of not making the		boulder' interfaces functionality	schedules continued to slide and change						
			planned R3.17 release. The		development.	priority during March, largely due to						
			Single Sign on components of		BHA to add more resources to	dependencies working directly with multiple						
			the HHIE interface are also		support the development of "big	third-party entities (HSRI, CAFAS, HHIE ADT,						
			currently at risk of not		boulder' interfaces functionality.	eRX). It is projected that some of the 'Big						
			making the planned R3.17			Boulder' items will not be implemented by the						
			release, and the ADT/Labs			end of the DDI period. The Project's updated						
			components have already			Draft Feature Roadmap currently includes the						
			missed needed intermediate			following:						
			target dates for the planned			R3.23 (4/28/2022) - Golden Record Project,						
			R3.17 release. The Project			DDD Provider Portal, Rollout, CAMHD Customer						
			will need to re-assess the			Portal MVP, Transition Billing Process to						
			planned implementation			INSPIRE, MQD Rate Change, IMHE Power App,						
			dates for these 'big boulder'			Automated Testing, Dashboards and Reports						
			interfaces, including			R3.24 (6/9/2022) - CAMHD Customer Portal						
			identification of the timing			MVP, MQD Eligibility Interface, Advanced						
			needs by the business teams.			Analytics Project, CAMHD Provider APIs, CAFAS						
			At a minimum, the CAFAS			Interface, Automated Testing, and Dashboards						
	1	1	and HHIE interfaces are	1	1	and Reports		1	1	1		
								II .		1		
			needed by the program.			R3.25 (7/21/2022) - Advanced Analytics						
			needed by the program. IV&V also notes that there			Project, ePrescribe, CAMHD Provider API's,						
			needed by the program. IV&V also notes that there are several new high priority			Project, ePrescribe, CAMHD Provider API's, CAFAS Interface, Automated Testing, and						
			needed by the program. IV&V also notes that there are several new high priority requests related to the DDD			Project, ePrescribe, CAMHD Provider API's, CAFAS Interface, Automated Testing, and Dashboards and Reports						
			needed by the program. IV&V also notes that there are several new high priority			Project, ePrescribe, CAMHD Provider API's, CAFAS Interface, Automated Testing, and						

23	7/31/2021	The current DDI period expires at	The current Project Staffing	Existing contractual agreements	Obtain IAPDU approval from CMS.	02/28/2022 - The IAPDU was approved by	Droinet	Issue	Low	Closed	Darren Macdonald	
23	//31/2021	the end of December 2021 which	Model shows a planned	Existing contractual agreements.	Obtain IAPDO approvai from Civis.	Federal partners in early February, which	Project Management	issue	LOW	Closed	Darreir iviacuonaiu	
			The state of the s				ivianagement					
		will require RSM to transition of the				extended the DD&I effort through October						
		D365 solution to the State prior to	support starting in			2022. Transition from RSM will not be required						
		contract end.	September 2021 through			until approximately August 2022. Based on the						
			December 2021. Prior to this			extended time being available for transition						
			timeframe, BHA should			efforts, IV&V is closing this finding.						
			commence the development			01/31/2022 - There were no substantive						
			of a transition plan to ensure			changes to this finding observed during January						
			the appropriate replacement			as BHA continues to pursue CMS Federal						
			State resources are			funding approval for extending DD&I through						
			identified/secured and the			October 2022 followed by M&O through						
			necessary knowledge			September 2024. IV&V will continue to monitor						
			transfer sessions are planned			this finding until Federal funding approved.						
			and executed with RSM. BHA			12/31/2021 - There were no substantive						
			will need to be sure they are			changes to this finding observed during						
			ready to take on the			December as BHA continues to pursue CMS						
			development of user stories,			Federal funding approval for extending DD&I						
			testing, deployment, and the			through October 2022 followed by M&O						
			support and maintenance of			through September 2024. IV&V will continue to						
			the entire system by the end			monitor this finding until Federal funding						
			of the DDI period (December			approved.						
			2021).			11/30/2021 - There were no substantive						
						changes to this finding observed during						
						November. In late October, PAC approved the						
						funding request for extending DD&I through						
						October 2022 followed by M&O through May						
24	10/29/202	The R3.19 Solution Upgrade	Solution upgrades are	Daily Scrum Reporting	Ensure there are adequate and	11/30/2021 - R3.19 was promoted to	Project	Issue	High	Closed		Technical issue
		technical issues are delaying the	essential for keeping the		qualified resources to support the	production as an FSU on 11/14/2021 and	Management					resolved and were
		implementation of the release and	system current in order to		current Solution Upgrade	access to the development and test						attributed to the
		the ability for staff to develop and	gain access to new features		processes. This may require the	environments was again restored. Because the						following:
		test code.	that enhance productivity,		support from RSM resources to	solution upgrade was the first in five (5)						Import of solution
			eliminate bottlenecks and		provide assistance and knowledge	releases, the deployment process took						taking 1-2 hours,
			govern sensitive information.		transfer.	approximately 12 hours. This issue did have an						timed out in PROD,
			The current R3.19 solution		As appropriate, consult with RSM	impact both on the amount of DDI functionality						so had to restore and
			upgrade work efforts that		on best practices that BHA could	(reduced) included in downstream releases and						then restart from a
			includes patches for 5		employ to support the Solution	cost implications. IV&V has closed this finding,						previous point in
			releases (R3.15-R3.19) is		Upgrade.				l			time backup
			1 0100303 (113123 113123) 13		opgrade.	as it was alleviated by the R3.19 release on						
			causing technical issues. As a		opgrade.	as it was alleviated by the R3.19 release on 11/14/2021.						• Errors are vague –
- 1			1 '		opgrade.	,						sometimes
			causing technical issues. As a		Opgrade.	11/14/2021.						- 1
			causing technical issues. As a result, R3.19+ development		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution						sometimes
			causing technical issues. As a result, R3.19+ development and testing work is		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been						sometimes indicating "failure"
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test						sometimes indicating "failure" but actually
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgiaue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been						sometimes indicating "failure" but actually successful
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgiaue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing						sometimes indicating "failure" but actually successful • MS moving away
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this high						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which is changing the
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this high						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which is changing the availability of some
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this high						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which is changing the availability of some functionality / how
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this high						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which is changing the availability of some functionality / how • Corrupt MDA encountered in SIT
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this high						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which is changing the availability of some functionality / how • Corrupt MDA
			causing technical issues. As a result, R3.19+ development and testing work is hampered until these		Opgi aue.	11/14/2021. 10/31/2021 - Due to the current R3.19 Solution Upgrade technical issues, staff have been advised to stay out of the development and test environments until the issues have been resolved. As a result, development and testing for R3.19 and forward are affected by this issue. IV&V will continue to monitor this high						sometimes indicating "failure" but actually successful • MS moving away from Classic UI which is changing the availability of some functionality / how • Corrupt MDA encountered in SIT